NCT04208321View on ClinicalTrials.gov

Safety and Pharmacokinetics of VT-1598

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

December 27, 2021

Study Completion Date

December 27, 2021

Conditions
Coccidioidomycosis
Interventions
OTHER

Placebo

Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.

DRUG

VT-1598

VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.

Trial Locations (1)

78209-1015

ICON Early Phase Services Clinical Research Unit, San Antonio

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04208321 - Safety and Pharmacokinetics of VT-1598 | Biotech Hunter | Biotech Hunter